Financial Statements

Dr. Reddy's Laboratories Limited (RDY)

$54.66

+0.18 (+0.33%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) 156,023144,247128,646113,865-
Net Income 23,56817,23819,49818,7959,806
Stock Dividends 267-1,31519-12108,051
Dividend Paid -4,146-4,147-3,916-4,002-3,992
Retained Earnings 175,712156,023144,247128,646113,865

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 57,11152,33254,08857,869-
Annual Depreciation 24,10717,3404,3593,71068,912
Capital Expenditure -19,049-12,561-6,115-7,491-11,043
Net PPE 62,16957,11152,33254,08857,869

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -3,9453,9023,9944,568
New Purchases -68,429-78,573-111,918-75,418-88,972
Intangible and Goodwill 3,9453,9023,9944,5684,418

Dr. Reddy's Laboratories Limited income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Dr. Reddy's Laboratories Limited FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.